Article
Transforming growth factor beta1 genotype and change in left ventricular mass during antihypertensive treatment--results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
Clinical cardiology - 1 Mar 2004
Hallberg Pär, Lind Lars, Billberger Katarina, Michaelsson Karl, Karlsson Julia, Kurland Lisa, Kahan Thomas, Malmqvist Karin, Ohman K Peter, Nyström Fredrik, Liljedahl Ulrika, Syvänen Ann-Christine, Melhus Håkan
Abstract excerpt
BACKGROUND: Angiotensin II, via the angiotensin II type 1 (AT1) receptor, may mediate myocardial fibrosis and myocyte hypertrophy seen in hypertensive left ventricular (LV) hypertrophy through production of transforming growth factor beta1 (TGF-beta1); AT1-receptor antagonists reverse these changes. The TGF-beta1 G + 915C polymorphism is associated with interindividual variation in TGF-beta1 production. No study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.